Literature DB >> 7009309

Results of a 12-year randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices.

T B Reynolds, A J Donovan, W P Mikkelsen, A G Redeker, F L Turrill, J M Weiner.   

Abstract

During a 7-yr period (1967-1974), 89 patients with alcoholic liver disease and at least one severe upper gastrointestinal hemorrhage thought to be from esophageal varices entered a randomized, controlled trial of medical therapy vs. end-to-side portacaval shunt. Follow-up continued to September, 1979, so that all surviving patients had at least 5 yr observation after randomization. Among 45 patients randomized to surgical therapy, 4 did not receive portacaval shunt, for various reasons. Among shunted patients there were 11 episodes of upper gastrointestinal bleeding, none fatal and none thought to be from esophageal varices. Thirty-seven percent of eligible patients have had moderate or severe hepatic encephalopathy ascribed to the shunt. Of 44 patients randomized to medical therapy, 7 eventually received portacaval shunt after multiple bleeding episodes. Since randomization there have been 190 episodes of bleeding requiring 589 transfusions and resulting in 23 deaths from bleeding or hepatic failure precipitated by bleeding. THere are 12 survivors in the surgically treated group and 8 in the group treated medically. Life-table analysis shows a small increase in survival in the surgically treated group throughout the study, which is not statistically significant. From our data, we could not identify risk factors that would improve the selection of patients for medical or surgical therapy.

Entities:  

Mesh:

Year:  1981        PMID: 7009309

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

1.  UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

Review 2.  Long term management of oesophageal varices.

Authors:  S K Sarin
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  Portal hypertension--25 years of progress.

Authors:  B R MacDougall; D Westaby; L A Blendis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Transjugular intrahepatic portocaval shunt (TIPS) and hepatic vein-to-caval stenting as salvage treatment of portal hypertension secondary to neoplasm.

Authors:  R P Davies; G R Sissons; N A McIntosh
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Mar-Apr       Impact factor: 2.740

5.  TIPS for portal decompression to allow palliative treatment of adenocarcinoma of the esophagus.

Authors:  G Moulin; P Champsaur; J M Bartoli; C Chagnaud; H Rousseau; D Monges
Journal:  Cardiovasc Intervent Radiol       Date:  1995 May-Jun       Impact factor: 2.740

6.  Improved quality of life after distal splenorenal shunt. A prospective comparison with side-to-side portacaval shunt.

Authors:  G Spina; R Santambrogio; E Opocher; F Galeotti; G Cucchiaro; M Strinna; G Pezzuoli
Journal:  Ann Surg       Date:  1988-07       Impact factor: 12.969

7.  Mesocaval and distal splenorenal shunts: effect on hepatic function, hepatic hemodynamics, and portal systemic encephalopathy.

Authors:  R Herz; H J Halbfass; M Rössle; D Waldmann; W Gerok
Journal:  Klin Wochenschr       Date:  1985-05-02

8.  The Emory prospective randomized trial: selective versus nonselective shunt to control variceal bleeding. Ten year follow-up.

Authors:  W J Millikan; W D Warren; J M Henderson; R B Smith; A A Salam; J T Galambos; M H Kutner; J H Keen
Journal:  Ann Surg       Date:  1985-06       Impact factor: 12.969

Review 9.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

10.  Portal hypertensive gastric mucosa: an endoscopic study.

Authors:  A Papazian; A Braillon; J L Dupas; F Sevenet; J P Capron
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.